Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-Label, Drug-Drug Interaction, Study to Evaluate the Effect of ASC42 on the Pharmacokinetics of Atorvastatin Tablets in Healthy Volunteers (HVs)
Conditions
Interventions
Atorvastatin
ASC42
Locations
1
United States
ICON
San Antonio, Texas, United States
Start Date
August 8, 2022
Primary Completion Date
August 23, 2022
Completion Date
August 30, 2022
Last Updated
September 27, 2024
NCT00090662
NCT06716502
NCT06290258
NCT07310264
NCT07483606
NCT06342713
Lead Sponsor
Gannex Pharma Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions